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Abstract
Background: Increasing age is the biggest risk factor for dementia, of which Alzheimer’s disease is the commonest
cause. The pathological changes underpinning Alzheimer’s disease are thought to develop at least a decade prior
to the onset of symptoms. Molecular positron emission tomography and multi-modal magnetic resonance imaging
allow key pathological processes underpinning cognitive impairment – including β-amyloid depostion, vascular
disease, network breakdown and atrophy – to be assessed repeatedly and non-invasively. This enables potential
determinants of dementia to be delineated earlier, and therefore opens a pre-symptomatic window where
intervention may prevent the onset of cognitive symptoms.
Methods/design: This paper outlines the clinical, cognitive and imaging protocol of “Insight 46”, a neuroscience
sub-study of the MRC National Survey of Health and Development. This is one of the oldest British birth cohort studies
and has followed 5362 individuals since their birth in England, Scotland and Wales during one week in March 1946.
These individuals have been tracked in 24 waves of data collection incorporating a wide range of health and functional
measures, including repeat measures of cognitive function. Now aged 71 years, a small fraction have overt dementia,
but estimates suggest that ~1/3 of individuals in this age group may be in the preclinical stages of Alzheimer’s disease.
Insight 46 is recruiting 500 study members selected at random from those who attended a clinical visit at 60–64 years
and on whom relevant lifecourse data are available. We describe the sub-study design and protocol which involves a
prospective two time-point (0, 24 month) data collection covering clinical, neuropsychological, β-amyloid positron
emission tomography and magnetic resonance imaging, biomarker and genetic information. Data collection started in
2015 (age 69) and aims to be completed in 2019 (age 73).
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Discussion: Through the integration of data on the socioeconomic environment and on physical, psychological and
cognitive function from 0 to 69 years, coupled with genetics, structural and molecular imaging, and intensive cognitive
and neurological phenotyping, Insight 46 aims to identify lifetime factors which influence brain health and cognitive
ageing, with particular focus on Alzheimer’s disease and cerebrovascular disease. This will provide an evidence base for
the rational design of disease-modifying trials.
Keywords: Epidemiology, Life course, Genetics, Alzheimer’s Disease, Ageing, Magnetic resonance imaging,
Positron emission tomography, Cognition, Vascular disease, Birth cohort
Background
Dementia is the leading cause of death in England and
Wales, accounting for 11.6% of all deaths registered in
2015 [1]. As the population ages, the burden of neuro-
logical diseases and dementia in particular will increase
dramatically. Current estimates suggest that 44 million
people worldwide are currently living with dementia, and
this number is predicted to more than triple by 2050, by
which time the annual cost of dementia in the US alone
may exceed US$604 billion [2]. Estimates suggest that a
five-year delay in symptom onset would halve prevalence,
costs and burden [3]. Understanding the causes of
dementia, and lifestyle or pharmacological interventions
that can prevent or delay the onset of symptoms is
therefore a global priority.
Dementia is a clinical syndrome due to many underlying
diseases, of which Alzheimer’s disease (AD) is the
commonest single cause. AD is characterised histopatho-
logically by the accumulation of senile plaques mainly
composed of amyloid β (Aβ), neurofibrillary tangles
composed of hyperphosphorylated tau [4], and excess
neuronal cell loss (atrophy) in vulnerable regions, notably
the medial temporal lobe and parietal association cortices.
The emergence of techniques for studying biomarkers
allows for many aspects of AD pathology to be assessed in
vivo. In particular, positron emission tomography (PET)
using amyloid-specific tracers allows for quantification
of fibrillar amyloid burden; and modern multi-modal
magnetic resonance imaging (MRI) offers a non-invasive
way of determining brain volumes, cerebrovascular
disease, white matter tract integrity, brain perfusion,
functional connectivity, and brain microstructure. Apply-
ing many of these techniques to cohorts with rare, auto-
somal dominantly inherited forms of AD, sporadic AD,
and healthy older controls suggests that: (1) accumulation
of Aβ is seen in a significant proportion (up to a third) of
individuals in their 70s; (2) Aβ accumulation occurs prior
to, and is likely to trigger, the development of other patho-
logical processes core to AD, including the deposition and
spread of abnormally hyperphosphorlayed tau through
vulnerable networks, microglial activation, brain hypome-
tabolism, and increased rates of atrophy; and (3) these
processes all occur several years – and in the case of
amyloid deposition perhaps a decade or more – prior to
the development of symptoms [5, 6].
These findings have already led to important advances,
including (1) a re-conceptualisation of AD to include
healthy individuals at risk, with contemporary research
criteria now determining that asymptomatic individuals
with evidence for brain amyloid, brain amyloid + neurode-
generation, or brain amyloid + neurodegeneration + subtle
cognitive impairment can be designated as having pre-
clinical AD [7–9]; and (2) the advent of clinical trials in
asymptomatic participants either at risk of AD on the basis
of carrying a gene known to cause familial AD [10, 11] or
individuals with asymptomatic amyloidosis [12]. These
trials aim to modify aspects of AD pathology by slowing or
even reversing the development of brain pathology, and
delaying the onset of cognitive decline and ultimately the
clinical manifestation of AD dementia.
Our understanding of this presymptomatic period is,
however, far from complete. Evidence to date comes largely
from extrapolation of cross-sectional (or short-interval
longitudinal follow-up) studies to infer the sequence of
changes that occur over much longer periods [13]. Indivi-
duals selected for such studies often are not typical of the
population as a whole, with many having genetic risks
factors, concerns about cognition, or a family history of
dementia [14]. Little is known in the general population
about the factors that influence the development, sequence
and timing of the different pathologies implicated in AD,
and how they interact with other brain pathologies (e.g.
cerebrovascular disease) to influence cognitive function.
Consequently, the evidence base to inform the design
of clinical trials in the presymptomatic phase is cur-
rently limited.
In parallel with the need to identify preclinical AD for
interventional trials, it is also vital to understand what
influences an individual’s risk of developing AD and other
forms of late-life cognitive impairment. There are more
than 20 identified genetic risk factors for AD, most of
which exert only a small influence on risk, but together,
by way of a polygenic risk score, have been shown to
almost double case prediction from chance [15]. There is
evidence that education and physical exercise are protec-
tive, whereas mid-life hypertension, obesity and diabetes
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adversely influence risk [16]. However it is unclear
whether these factors act independently, cumulatively or
interactively, and how they influence different pathological
processes that can lead to dementia; to address these
questions requires prospective data across the life course.
The Medical Research Council (MRC) National Survey
of Health and Development (NSHD) has followed 5362
individuals since their birth in England, Scotland and
Wales during one week in March 1946 [17–19].
Repeated waves of data collection since childhood have
enabled detailed cognitive and physical phenotyping of
this population-representative cohort. Details of the
cohort are provided elsewhere [17, 18], with an overview
of relevant information collected to date in Table 1. Now
aged 71, members of this intensively-studied cohort are
at a critical age to investigate preclinical AD: old enough
to be at high risk for amyloid pathology, but several
years before the expected exponential rise in dementia
prevalence [20].
We describe here the study design and protocol of
“Insight 46”, a prospective longitudinal two time-point
(0, 24 month) sub-study of 500 study members, incor-
porating the collection of new clinical, neuropsycho-
logical, MRI, PET amyloid imaging, and blood and urine
biomarkers. We outline the study’s organisation and
funding structure, provide an overview of the recruit-
ment criteria, the cognitive, imaging and fluid biomarker
protocols, and the duty of care protocol. We summarise
the key hypotheses to be tested, and the data that are be-
ing collected; these data will in due course be made
available to the research community.
Methods/design
Study organisation/funding
Insight 46 is funded by grants from Alzheimer’s Research
UK (ARUK-PG2014–1946, ARUK-PG2017-1946 PIs
Schott, Fox, Richards), the Medical Research Council
Dementias Platform UK (CSUB19166 PIs Schott, Fox,
Richards), the Wolfson Foundation (PR/ylr/18575 PIs Fox,
Schott), the Medical Research Council (MC_UU_12019/1
PI Kuh and MC_UU_12019/3 PI Richards), the Wellcome
Trust (Clinical Research Fellowship 200109/Z/15/Z
Parker) and Brain Research Trust (UCC14191, PI Schott).
AVID Radiopharmaceuticals (a wholly owned subsidiary
of Eli Lilly) provide the PET amyloid tracer (Florbetapir)
but had no part in the design of the study.
Separate ethical approvals for NSHD have been
provided by Research Ethics Committees in England and
Scotland outlined elsewhere [17, 19, 21]. Ethical ap-
proval for the neuroscience sub-study was granted by
the National Research Ethics Service (NRES) Committee
London (REC reference 14/LO/1173, PI Schott). All par-
ticipants provide written informed consent to participate
Table 1 Overview of life course data available for MRC NSHD study participants
Time point (ages)
1946
(birth)
1947–50
(1–4 yrs)
1951–61
(5–15 yrs)
1962–77
(16–31 yrs)
1978–2003
(32–57 yrs)
2006–10
(60–64 yrs)
2014–15
(68–69 yrs)
Number of data collections 1 2 8 8 3 1 1
Measure Social factors Socioeconomic position ✓ ✓ ✓ ✓ ✓ ✓ ✓
Social function (contacts, support,
participation)
- - - - ✓ ✓ ✓
Occupation - - - ✓ ✓ ✓ ✓
Educational Qualifications ✓ ✓
Psychological
measures
Behaviour and mental health - ✓ ✓ ✓ ✓ ✓ ✓
Physical and health
measures
Survival and morbidity ✓ ✓ ✓ ✓ ✓ ✓ ✓
Anthropometric measures ✓ ✓ ✓ ✓ ✓ ✓ ✓
Smoking status - - - ✓ ✓ ✓ ✓
Exercise and physical health - - ✓ - ✓ ✓ ✓
Diet - ✓ - - ✓ ✓ ✓
Respiratory function - - - - ✓(36, 43, 53) ✓ ✓
Cardiovascular function - - - - ✓(36, 43, 53) ✓ ✓
Musculoskeletal measures - - - - ✓ (53) ✓ ✓
Blood sample - - - - ✓ (53) ✓ ✓
Urine sample - - - - - ✓ -
Cognition Cognitive function
(verbal/non-verbal)
- - ✓ (8, 11, 15) ✓ (26) ✓ (43, 53) ✓ ✓
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and for their data to be stored in accordance with the
Data Protection Act.
Participants’ recruitment and clinical protocol description
Participants
To capitalise on the life course data and to avoid a priori
decisions as to who might be at risk of cognitive decline,
entry criteria to the sub-study are based only on maximi-
sing the life course data available for analysis. A sample of
500 NSHD study members are being selected at random
from those who attended a clinic-based assessment age
60–64, had previously intimated they were willing to
attend a clinic visit in London and for whom relevant data
in childhood and adulthood are available. These relevant
data are shown in Table 2.
The first 500 study members fulfilling these criteria
and agreeing to participate will be included. Excluded
are individuals with contraindications to MRI or PET
including, but not limited to, claustrophobia, metallic
implants such as pacemakers, or research nuclear
medicine scans within the last year that would result
in an individual exceeding acceptable mandated yearly
radiation exposures. Where appropriate, the option to
consent to post-mortem brain donation is discussed
with participants. A flowchart outlining the study is
shown in Fig. 1.
Duty of care
A duty of care protocol building on the NSHD proto-
col used in 2006–10 and in accordance with the
MRC/Wellcome Trust guidelines is being imple-
mented for the purpose of feeding back health-related
findings in research [22] to each participant and their
GP. Participants are given the option of ‘opting out’
from receiving any correspondence regarding report-
able findings, but must consent to their GP receiving
the information. Anthropomorphic measures (height
and weight), recumbent blood pressure, audiometry
and a range of standard clinical blood tests (haemo-
globin, platelet count, vitamin B12, urea, creatinine,
random glucose and TSH) together with their normal
ranges are routinely reported. Participants with results
outside the normal range are advised to discuss the
results with their GP in a timely fashion. If blood re-
sults are significantly outside the normal range, falling
beyond pre-specified ‘Action’ levels, the study clinician
contacts the participant and GP via telephone within
48 h of receipt of results.
All T1, T2 and FLAIR volumetric MRI sequences are
reviewed by a consultant neuroradiologist at the National
Hospital for Neurology and Neurosurgery. The study
follows guidelines based on the UK Biobank imaging
study (www.ukbiobank.ac.uk/wp-content/uploads/2016/11/
Incidental-findings-list-of-possible-abnormalities.pdf ), and
information is only fed back to study members and
their GP if there is an MRI abnormality that might
require treatment or surveillance. A list of potential
findings considered reportable are summarised in Table 3.
The ethical challenges of providing information regarding
amyloid PET results in cognitively-normal individuals
has been discussed elsewhere [23], and for this study
amyloid PET status is not fed back to study members.
In addition, information is fed back to participants and
their GP if clinical assessments reveal clear evidence of
significant cognitive impairment (based on a MMSE
score ≤ 24 and/or significant concern from study clin-
ician) or clinically detectable parkinsonism (i.e. fulfilling
Queen Square Brain Bank criteria [24] for Parkinson’s
disease (PD)) in previously undiagnosed individuals.
Appendix 1 summarises reportable findings and normal
ranges employed in Insight 46.
Clinical, neurological, cognitive and sensory assessments
All individuals are assessed at a single site (UCL). Partici-
pants complete four self-administered questionnaires;
undergo a structured clinical interview with a neurologist;
have a structured neurological examination; undergo
neuropsychological testing, and assessment and testing of
auditory, olfactory and visual function. These assessments
have been designed to be administered in divided sessions
that last less than four hours during a single day (mean
duration =199 min based on six pilot visits).
Self-administered questionnaires
The state and trait anxiety inventory [25]: This 40-item
questionnaire assesses an individual’s thoughts and feel-
ings, and is designed to quantify anxiety levels at the
present moment and in general.
Table 2 Minimum life course dataset for Insight 46
Attendance at a clinic visit at age 60–64
Parental socioeconomic position: at least one indicator of
occupational social class or education
Cognition: memory and processing speed from the 60–64
year collection AND at least one set of measures at either
ages 8, 11 or 15
Early physical growth trajectories: birth weight and at least
one measure of height and weight at ages 4–15
Educational attainment: highest qualification by age 26
Mental health: teacher ratings of behaviour and temperament
at ages 13 or 15, and at least one measure of affective
symptoms at ages 36, 43, 53 or 60–64
Blood pressure, lung function, adult height and weight:
at least one measure of each at ages 36, 43, 53 or 60–64
Health behaviours: at least one measure of smoking and
physical exercise at ages 36, 43, 53 or 60–64
Blood: either age 53 or 60–64 samples
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A dental health questionnaire [26]: There is growing
evidence that periodontitis is a risk factor for sporadic
AD and it has been postulated that periodontal patho-
gens may drive chronic neuro-inflammation contributing
to Alzheimer’s pathology [27]. This self-administered
questionnaire utilises eight questions designed to assess
the likelihood of periodontitis.
A handedness questionnaire [28]: Hand preference is
closely related to cerebral dominance [29]. This
questionnaire asseses hand preference for 12 different
tasks using a numerical scale enabling quantification of
each participant’s handedness (range − 24 to +24).
Screening question for Rapid Eye Movement (REM)
sleep behaviour disorder [30]: REM sleep behaviour
disorder is a known risk factor for the emergence of
MRC National Survey of Health and Development 
(NSHD)
Original 1946 cohort: 5,362
~2,700 in active follow up as of January 2015
500 will be randomly recruited to participate  in
Insight 46
Screening Phone Call by Study 
Clinician:
• Overview of study
• Check for exclusion criteria  
• Gain permission to notify GP of study 
participation and certain results
• Arrange for the participant 
coordinator to call back to finalise  
testing date and arrange travel 
logistics
Logistics Phone Call 
by Participant 
Coordinator:
• Confirm visit date
• Arrange travel and 
hotel
• Obtain contact 
information for 
AD8 questionnaire
Participant Confirmation 
Letter:
• Cover letter confirming visit 
details 
• Travel itinerary
• Family history questionnaire 
• PET/MRI information 
brochure
• Expenses guidelines
• Brochures with local 
attractions, food, and 
amenities
Reminder Phone Call:
• Confirm visit details as 
outlined in 
Confirmation letter
• Reminders to wear 
appropriate clothing 
and bring list of 
prescribed or over-the-
counter medication.
Study Day:
• Consent and clinical interview
• Blood and urine collection
• Neuropsychology testing
• Neurological examination
• Sensory testing
• Transfer to PET/MRI scanning 
department for scan
Post-visit Phone Call 
by Study Clinician:
• Report blood 
results
• Provide advice if 
any adverse events 
are reported and 
provide additional 
follow up if 
necessary
Duty of Care:
• Send  GP letter with 
anthropometry, 
audiology, BP, routine 
blood results
• Inform GP (and 
participant if requested) 
if clinically-significant 
findings detected on 
neurological 
assessment, cognitive 
assessment or MRI 
radiological read
1,690 attended a clinic 
visit at ages 60-64 years, 
1,377 have a minimum 
data set
Fig. 1 Flowchart for Insight 46
Table 3 Reportable MRI brain findings
Acute brain infarction
Acute brain haemorrhage (note: not old bleeds)
Intracranial mass lesions (note: not meningiomas in locations
considered highly unlikely to cause problems)
Suspected intracranial aneurysm or vascular malformation (inc.
cavernomata) (note: not aneurysms less than 7 mm in diameter)
Colloid cyst of the 3rd ventricle
Acute hydrocephalus
Significant sinus disease with suspicion of underlying pathology
(e.g. unilateral sinus opacification)
Other unexpected, serious, or life-threatening findings
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Parkinson’s disease and related disorders. A yes/no
answer is obtained to the question “Have you ever
been told, or suspected yourself, that you seem to ‘act
out your dreams’ while asleep (for example, punching,
flailing your arms in the air, making running move-
ments, etc.)?”. This has a sensitivity of 93.8% and a
specificity of 87.2% for detecting REM sleep behaviour
disorder [30].
Clinical interview
A standard personal and family history of neuro-
logical illness or cognitive impairment and a medica-
tion history is obtained. In addition, participants are
screened for measures of self-perceived cognitive
decline using the SCD-Q part I (MyCog) question-
naire [31] and are asked questions that enable coding
of essential features of subjective cognitive decline as
outlined by the working group of the Subjective
Cognitive Decline Initiative [32]. A corroborative
history regarding each participant’s cognitive func-
tioning is obtained using the AD8 screening tool, an
informant questionnaire administered in person or
via the telephone by the study clinician. The AD8
correlates well with the clinical dementia rating scale
(CDR), and has high sensitivity and specificity for
detecting cognitive impairment [33, 34].
Physical and neurological examination
A physical examination comprises anthropomorphic
measures (weight in kilograms and height measured to
the nearest mm), and lying and standing blood pressure
at three minutes to assess for evidence of orthostatic
hypotension (OMRON HEM-905; OMRON Healthcare
UK Ltd., Milton Keynes).
Patients with AD and other forms of dementia have
more marked decline in motor function, including gait,
than healthy controls, with the possibility that these
changes may precede the onset of frank cognitive symp-
toms [35, 36]. This is perhaps not surprising if gait is
viewed as a complex cognitive task, requiring an interplay
of attention, executive function and visuospatial function,
in addition to the motor processing functions of the
motor cortex, basal ganglia and cerebellum. It has
therefore been suggested that changes in gait and motor
skills in general may reflect and correlate with early cogni-
tive change [37].
Participants’ self-paced gait is assessed over a 20-
m distance in isolation and while performing a cog-
nitive task (single-letter-cued (phonemic) fluency
and dual-letter-cued (phonemic) alternate fluency),
and wearing an accelerometer on the lower back
(LPMS-B inertial measurement unit (Life perform-
ance Research Inc)), with data analysis using a
custom program written in LabVIEW2010 (National
Instruments, Ireland). Temporal (step time and
cadence) as well as spatial (step-, stride-time, walk-
ing speed) parameters can be derived. More in-
depth analysis utilising temporal-spatial parameters
and participant metadata can describe parameters
indicating motor control [38]. Non-linear or phase
plot analysis can be used to explore subtle gait
changes using the whole dataset of a particular
participant. Using this approach, it has been demon-
strated that changes in gait can be detected in the
pre-symptomatic phase of Huntington’s disease [39].
Although parkinsonian features are generally con-
sidered to be later clinical manifestations in AD, it
has been reported that parkinsonian features may
precede the onset of frank dementia [40, 41]. A
standardised neurological examination includes the
MDS-Unified Parkinson’s Disease Rating Scale
(UPDRS) Part III (Motor) [42], which quantifies
presence of tremor, bradykinesia, rigidity, postural
instabilty and gait disorder. Assessments are video-
taped for quality control purposes and to enable
futher review by a senior neurologist if clinically-
significant parkinsonian features are identified. The
Bradykinesia Akinesia Incoordination (BRAIN) test is
administered to all participants via a laptop (Lenovo
Thinkpad, Lenovo Group Ltd). This computer keyboard-
tapping task was originally developed for use in assessing
the effect of symptomatic treatment on motor function in
Parkinson’s disease. An online version has been
designed and validated which can be utilised as an
objective longitudinal measure of emerging motor
dysfunction [43]. The outputs of the BRAIN test
include a kinesia score (KS30, number of key taps in
30 s), akinesia time (AT30, mean dwell time on each
key in ms), incoordination score (IS30, variance of
travelling time between key presses) and dysmetria
score (DS30, accuracy of key presses).
Cognitive battery
The cognitive assessment battery is based on a re-
view of results and cognitive protocols from several
large-scale initiatives and clinical trials involving
individuals at risk for AD [10, 12, 44], and is
complementary to cognitive assessments performed
as part of the most recent (in some cases concur-
rent) NSHD home visit (that includes the ACE-III
[45] and word-list learning [46]). Complementing
ongoing work with the whole NSHD cohort, participants’
cognitive trajectories will be assessed prospectively
over the two time points, and retrospectively using
previously collected cognitive measures (refer to Appendix 2
for an overview of neuropsychometric tests collected
to date).
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The battery includes:
The mini-mental state examination (MMSE) [47]
The MMSE is a widely used 30-point screening tool for
cognitive impairment within clinical practice, assessing
multiple cognitive domains including: i) orientation to
time and place (10 points); ii) registration (3 points); iii)
attention +/− calculation (5 points); iv) recall (3 points); v)
language (2 points); vi) repetition (1 point); vii) reading (1
point); viii) writing (1 point); ix) visuospatial function (1
point); x) following a 3-stage command (3 points).
Logical memory from the Wechsler Memory Scale-Revised
(WMS-R) [48]
The Logical Memory test assesses free recall of a short
story that contains 25 details. The participant is asked to
recall the story immediately and after a delay of approxi-
mately 20 min.
Digit-symbol substitution test, from the Wechsler Adult
Intelligence Scale-Revised (WAIS-R) [49]
The Digit-Symbol Substitution test explores attention
and psychomotor speed. Participants are given a code
table displaying the digits from 1 to 9, each paired with
a symbol. On a worksheet printed with rows of digits,
participants are asked to fill in the corresponding symbol
under each digit as shown in the code table, as quickly
and accurately as possible. The score is the number of
symbols completed correctly within 90 s.
Matrix reasoning from the Wechsler Abbreviated Scale
of Intelligence (WASI) [50]
The Matrix Reasoning test assesses non-verbal reason-
ing. Participants are shown a matrix of geometric shapes
with a section missing and are required to select the
missing piece from five options. There are 32 matrices,
graded in difficulty, and the test is discontinued when
participants reach a certain error threshold, as specified
in the WASI manual.
Five more novel tests, intended to detect subtle, early
cognitive deficits, are also being administered (see Fig. 2).
Task-set switching / response inhibition [51, 52]
A meta-analysis of relationships between amyloid
burden and cognition in cognitively-normal older adults
found evidence of an association between amyloid bur-
den and executive functioning [53]. This task examines
the relationship between two important executive func-
tions – task-set switching and response inhibition –
which are vulnerable in early AD [54, 55]. Individuals
are presented with a computer screen on which a stimu-
lus is displayed, and a response box with two buttons.
The first part of the experiment comprises the simple
choice “arrow only” and “word only” conditions, which
complements the simple choice reaction time tasks ad-
ministered at 60–64 years. In the “arrow only” condition,
participants are shown the cue ‘arrow’ for 1000 ms,
followed by an arrow pointing left or right. In the “word
only” condition, participants are shown the cue ‘word’
for 1000 ms, followed by the word ‘left’ or ‘right’. In each
case they must press the button that corresponds to the
stimulus, using the index and middle fingers of their
dominant hand. The second part of the experiment is a
switching condition in which the cue may be either
‘arrow’ or ‘word’, and the stimulus is a combined arrow
and word. The stimulus is either congruent (e.g. left
arrow and the word ‘left’) or incongruent (e.g. left arrow
and and the word ‘right’). Trials in the switching task are
categorised into switch and non-switch. In a non-switch
trial the cue is the same as for the immediately prece-
ding trial, whereas in a switch trial the cue differs from
the immediately preceding trial. In order to evaluate the
effect of preparation time on task-set switching and
response inhibition, the cue is shown for either a short
(200 ms) or long (1500 ms) interval before the stimu-
lus appears. Outcome measures are reaction time and
error rate.
‘What was where?’ visual short-term memory binding
task [56, 57]
This test requires participants to view one or three
fractal objects, presented simultaneously in random
locations on the screen. Participants are asked to
remember both the objects and their locations. After a
delay of one or four seconds they are required to make a
forced choice between two fractals, one of which was
displayed in the initial memory array (the target) and
the other of which is a ‘dummy’ fractal. Participants are
required to touch the object they think has been
previously presented and ‘drag’ it on the touch screen to
its remembered, original location. Outcome measures
are the proportion of fractals correctly identified, and
the localisation error (i.e. the distance between the loca-
tion reported by the participant and the true location of
the target in the initial memory array) and the propor-
tion of ‘binding errors’. A binding error occurs when a
participant chooses the correct fractal but drags it to
the location of one of the non-target (unprobed) fractals
from the initial array. The binding of such featural
information has been shown to be vulnerable in asymp-
tomatic familial AD mutation carriers [58, 59]. There is
evidence that binding ability is relatively preserved in
normal ageing despite the age-related decline in mem-
ory for object identification and localisation, making it a
promising target for sensitive tests to detect preclinical
AD [60].
Visuomotor integration
This is a circle-tracing task which includes both direct
and indirect visual feedback conditions. The task is
presented on a tablet laptop, with the screen placed flat
on the table in front of the participant, with an
additional free-standing monitor behind it. Participants
are asked to use a stylus to trace round a circle on the
tablet as quickly and accurately as possible. In the direct
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condition, participants can see their hand and the path
they are tracing on the tablet. In the indirect condition,
participants put their arm under a box so they cannot
see their hand, but they are instructed to look at the
free-standing monitor to view a copy of the circle and
their tracing path. Continuous performance measures
are provided including accuracy, speed and speed of
error detection and correction. The test has revealed
changes in speed and accuracy in Huntington’s Disease
mutation carriers more than 10 years before expected
age-of-onset [61].
12-item Face-Name Associative Memory Exam (FNAME-
12A)
The FNAME-12A is a modified version of the 16-item
Face-Name Associative Memory Exam (FNAME-16). The
FNAME-12A has fewer stimuli and additional learning
trials which are well tolerated by those with mild
cognitive impairment (MCI), while remaining challenging
in cognitively-normal older adults [62]. It has demon-
strated psychometric equivalence with the FNAME-16,
which is related to β-amyloid burden in cognitively-
normal older people [63]. The FNAME-12A requires the
participant to learn 12 face-name and face-occupation
pairs. Participants are given two exposures to all 12 face-
name/occupation pairs. After each exposure and following
a 10-min delay they are asked for the name and occupa-
tion associated with each face. After a 35-min delay they
are shown three faces and asked to identify each previ-
ously learned face from two distractors (facial recognition)
and to recall the name and occupation. If they cannot
remember the name or occupation, they are provided with
three recognition choices.
Fig. 2 Novel computerised tests (a) Irrelevant Distractor. An example stimulus display (not to scale) with an irrelevant distractor in the low load
condition. Note that the specific cartoon image shown here as an irrelevant distractor is included for illustrative purposes only, in order to avoid
violating copyright for the images used in the experiment. Figure reprinted from [64] with permission from American Psychological Association
(b) Visuomotor Integration apparatus. Note that in the indirect condition, the participant’s hand is covered by a box, not shown here.
Figure reprinted from [61], Copyright, with permission from Elsevier. (c) ‘What was where?’ task. Figure reprinted from [56] available from
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360752/, American Psychological Association, copyright under the Creative Commons
Attribution License https://creativecommons.org/licenses/by/3.0/ (d) Task-set Switching / Response Inhibition. An example stimulus display for an
incongruent word trial
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Irrelevant distractor paradigm [64, 65]
Participants are given a computerised letter-search
task and are required to make a rapid decision as to
which target letter (‘X’ or ‘N’) has appeared in the search
display. There are three load conditions, high (four
letters), medium (three letters) and low (one letter). On
some of the trials, a distractor appears on the outside of
the search display. This distractor can either be task-
irrelevant (a cartoon character) or task-relevant (the
letter X or N). The task-relevant distractors can be
congruent or incongruent to the target letter. Outcome
measures are reaction time and error rate. The task
evaluates the extent to which attention is captured by
the different distractors, and the role of perceptual load
in this process.
These tasks give weight both to response accuracy and
latency to maximize detection of subtle cognitive change
and discriminate cortical/subcortical dysfunction.
Cognitive performance at the 2-year follow up in the
sub-study will be evaluated against study baseline
performance and cognitive performance in childhood,
adolescence and adulthood.
Sensory function
There is increasing interest in the possibility that impaired
visual function, sense of smell and hearing may provide
signals of preclinical AD [66–70]. As such, participants
will have comprehensive sensory assessments of vision,
olfaction and both peripheral and central auditory function.
Basic parameters of visual function, an important factor
contributing to deficits experienced in elderly patients with
cognitive impairment, are assessed using The Portable Eye
Examination Kit (PEEK), a smartphone application that
measures visual acuity, colour vision and contrast sensitiv-
ity [71].
The University of Pennsylvania Smell Identification Test
(UPSIT) is a commercially-available, well-established,
reliable, and standardized olfactory test that can be self-
administered [72]. The ‘British’ version is being used as it is
the most culturally appropriate to the NSHD. Each test
comprises four 10-page booklets with one odorant (embed-
ded in 10–50-μm diameter microcapsules fixed in a propri-
etary binder and positioned on brown strips) at the bottom
of each page. Accompanying each strip is a multiple-choice
question with four responses following an alternative
forced-choice paradigm. Packs are provided to participants
to complete at home and returned using a pre-paid enve-
lope provided. Participants are also asked prior to testing
whether they have subjectively noticed a decline in their
sense of smell.
Peripheral hearing is assessed using air conduction
threshold audiometry, with pure tones presented to
each ear at different frequencies covering the range
of human speech perception (0.5 kHz - 4 kHz). A
testing procedure in keeping with British Society of
Audiology recommendations [73] is used in which
the sound level of the tones are varied and enable
hearing thresholds for each ear at each frequency to
be obtained.
Central auditory processing is tested by using a word
identification in background noise paradigm [74]. This
involves presentation of high-frequency monosyllabic
words embedded in a multi-talker babble noise com-
posed of 20 voices. The background noise is presented
at a fixed level of 65 dB SPL, while the sound level of
each individual word is varied according to an adaptive
staircase procedure based on whether participants are
able to identify the word correctly. This is designed to
obtain a “speech reception threshold”, which quantifies
participants’ ability to identify spoken words in back-
ground noise.
Imaging protocol description
Imaging is performed on a Biograph mMR 3 T PET/
MRI scanner (Siemens Healthcare, Erlangen), allowing
for simultaneous acquisition of dynamic amyloid PET
and MR data whilst minimising scanning time and
exposure to radiation (compared with the use of PET-
CT). Participants will have one scanning session at
each time point. The neuroimaging protocol
comprises both structural and functional acquisitions,
and is designed to be completed within a 60-min
scanning session.
Amyloid load is assessed using the 18F amyloid PET
ligand, florbetapir. Amyloid positivity on florbetapir-
PET imaging is correlated with post-mortem Aβ
burden, neuritic amyloid plaque density, and neuro-
pathological diagnosis of AD [75]. After intravenous
cannulation, 370 MBq florbetapir F18 (Amyvid) is
injected. PET data are acquired continuously during
and following injection to allow florbetapir uptake
dynamics to be assessed. Final amyloid burden is
assessed over a 10-min period, ~50 min after injection,
with scope for the previous 10-min period to be used
if longer scan periods are not tolerated. PET data, ac-
quired in list-mode, is reconstructed using a 3D
ordered-subset expectation-maximisation algorithm
with three iterations and 21 subsets, and smoothed
with a 4 mm Gaussian kernel. Attenuation maps are
computed by default from the ultra-short echo time
(UTE) sequences provided by the vendor as well as
from the T1-weighted and T2-weighted volumetric
scans using a multi-atlas CT synthesis method [76],
also known as pseudo-CT (pCT). The latter approach
significantly improves PET reconstruction accuracy
when compared to the UTE-based correction [77], as
demonstrated in Fig. 3.
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For the MR acquisitions, a body coil RF transmitter is
used in conjunction with a 12-channel receiver array
head coil. The maximum gradient strength is 45mT/m
along each direction. The MR sequences are:
(i) high resolution 3D T1-weighted, T2-weighted and
FLAIR volumetric scans;
(ii) resting state functional MRI (rs-fMRI);
(iii)multi-shell high angular resolution diffusion-weighted
MRI (DW MRI);
(iv) a multi-echo 3D gradient echo sequence for
simultaneous T2*-weighted/susceptibility-weighted
imaging (SWI), quantitative susceptibility mapping
and b0 field mapping; and.
(v)arterial spin labeling (ASL) for quantitative mapping
of cerebral blood flow (CBF).
An additional b0 field map is also acquired for
distortion correction of the rs-fMRI and DW MRI
images. Full details of the acquisition parameters are
shown in Table 4.
3D volumetric scans (T1, T2 and FLAIR)
Three volumetric scans are acquired with matched
spatial coverage, resolution and complementary con-
trasts, to aid tissue segmentation, delineation of the
intracranial vault, and white-matter lesion visualization.
3D T1-weighted images are obtained using an MPRAGE
sequence [78]. This is optimized to provide strong con-
trast between white matter and grey matter and enable
quantification of grey matter macroscopic structures in
both cortical and subcortical brain regions. 3D T2-
weighted images use a long echo train turbo spin echo
sequence (SPACE) [79]. FLAIR images are acquired
using the same SPACE sequence as T2-weighted images
but with the addition of an inversion preparation pulse
to null signal from cerebrospinal fluid. T2-weighted and
FLAIR images are sensitive to white-matter lesions and
hyperintensities, which are typically seen in association
with cerebrovascular disease.
Images undergo manual QC in line with protocols
developed for commercial trials, by a trained team who
assess motion, coverage and other issues. T1 scans are
additionally checked specifically for blurring, image
wrap-around and contrast problems, and FLAIR for
good CSF suppression.
Pre-processing of structural (T1, T2, FLAIR) images
is carried out by applying a correction for gradient
non-linearity [80] followed by brain-masked (by regis-
tration of MNI template to the scan) N4-bias correc-
tion [81]. An automated multi-region parcellation of
the T1 images is carried out using geodesic informa-
tion flow (GIF) [82] – demonstrated in Fig. 4. The
parcellation is transferred to microstructure, PET,
ASL and fMRI maps for the purpose of region-of-
interest (ROI)-based analysis following registration of
those images to the T1 image.
Resting state fMRI (rs-fMRI)
Resting state, or task-free, fMRI (rs-fMRI) allows for
assessment of functional cortical connectivity through
analysis of resting state networks (i.e. disparate brain
Fig. 3 Improved PET reconstruction using the pCT method. Examples of attenuation maps obtained with the multi-atlas CT synthesis method
(pCT) and the UTE method and the corresponding florbetapir PET images generated with each method (10-min frame 50 min post-injection).
Difference maps are also shown (pCT – UTE) to better visualise the improved PET reconstruction accuracy
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regions which exhibit synchronised fluctuations in local
cerebral blood flow while the brain is not engaged in any
specific task), which are thought to represent cortical
networks critical to the functional organisation of the
brain [83].
rs-fMRI is acquired using a T2*-weighted gradient
echo EPI acquisition scheme. A resolution of 3x3x4mm3
was chosen to ensure whole brain coverage (defined
as 144 mm coverage in the inferior-superior direction
for angled transverse slice orientation [84]) within a
reasonable relaxation time (TR) (~2 s). Parallel im-
aging is also used to accelerate the imaging and re-
duce image distortions (GRAPPA with acceleration
factor 2). At the beginning of the rs-fMRI acquisition,
participants are asked to “close their eyes and not to
fall asleep” for the duration of the scan.
Individual fMRI time series are visually checked for
head coverage, motion, signal dropout and other ar-
tefacts. All fMRI volumes are realigned to correct for
motion between individual points in the time course.
A plot of the registration parameters computed in
the motion correction is provided for manual review
to ensure that the level of motion is not severe
enough to adversely affect the resulting analysis.
Signal quality metrics such as signal-to-noise ratio
(SNR), variance of signal change from average signal
(DVARs) and spike levels are also plotted over the
length of the time course [85]. Timepoints that are
outliers are automatically removed from the analysis.
The motion-corrected fMRI time course is then
registered to the corresponding anatomical T1
image. A cohort specific group template discretised
in MNI space is iteratively computed by mapping
all T1 images with 10 (1 rigid, 9 affine) and 10
non-linear registrations into the MNI image space
[86]. The fMRI scan is then transformed into the
template space by combining the affine registration
from fMRI to T1 image with the transformation
that maps the individual T1 image into the group
template in MNI space. A Generalised Linear Model
(optimised with restricted maximum likelihood esti-
mation (REML) [87]) is used to account for signal
drifts and physiological noise using cosine basis func-
tions (highpass filtering of frequencies >0.01 Hz), the
demeaned motion-realignment estimates and their
derivatives, and RETROICOR regressors, where ap-
propriate [88].
Two methods of analyzing the pre-processed data will
be used: a seed-based method and independent compo-
nent analysis (ICA) [89]. In brief, the remaining residuals
Fig. 4 Volumetric T1 pre-processing and segmentation in Insight 46. Examples of axial (top row), coronal (middle row) and sagittal (bottom row)
slices from an original MPRAGE volumetric T1 scan (left column), pre-processed T1 (distortion and bias field corrected) (middle column), and with
the GIF parcellation overlaid on top (right column)
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are smoothed (Gaussian smoothing kernel with 5 mm
FWHM) and mapped into the subsampled group
space to create spatial correspondence among indi-
vidual brains. A seed region is chosen to extract an
average time course that is correlated with the time
course of every individual voxel. The resulting cor-
relation map per participant is Fisher z-transformed
to enable t-test hypothesis testing among partici-
pants. For the ICA, time courses of the motion-
realigned fMRI scan within a mask of the brain are
extracted, centered and variance-normalized, resulting
in one voxel-time matrix per participant. All participant
matrices are then concatenated in time. The obtained
group matrix is reduced to its principal components
and whitened. The independent component analysis
[90] is applied to the whitened group matrix to obtain
spatial components. The representation of all group-
independent components in each participant is
required for group comparison. Dual regression will be
applied to obtain group-independent component repre-
sentations in each participant.
Diffusion-weighted MRI
Diffusion-weighted MRI is a technique that enables
characterisation of the microstructural integrity of
white and grey matter. The majority of studies inves-
tigating neurodegeneration utilise the diffusion tensor
model [91], which aggregates the differential diffusion
profiles of water molecules in extra- and intracellular
spaces to produce an array of metrics including
fractional anisotropy (FA), axial diffusivity (AxD),
radial diffusivity (RD) and mean diffusivity (MD).
These metrics have been used to demonstrate change
in white-matter tract integrity and grey-matter micro-
structure in AD [92]. However, this model does not
account for multiple fiber orientations or tissue
compartments within a voxel, making interpretation of
changes in these metrics ambiguous. Neurite orientation
dispersion and density imaging (NODDI) [93] is a
recently-developed multi-shell diffusion technique which
allows for the estimation of tissue microstructure at the
sub-voxel level by assuming that water protons in
neuronal tissue can be considered to be in three different
pools: i) free water, modelling CSF space; ii) restricted
water, modelling dendrites and axons; and iii) hindered
water, modelling diffusion within glial cells, neuronal cell
bodies and the extracellular environment. This more
complex modelling enables estimation of neurite density
(neurite density index (NDI)) and neurite orientation
dispersion (orientation dispersion index (ODI)) in both
white and grey matter.
Diffusion MRI is acquired using a twice-refocused
spin echo EPI sequence [94, 95] with two non-zero b-
values (700 and 2000 s/mm2) and multiple directions
(32 and 64 directions for the b = 700/2000 s/mm2
scans respectively). The b-vector directions were
calculated to be uniformly distributed over a hemi-
sphere, and images with b = 0 s/mm2 are interspersed
throughout the acquisition (12 obtained overall). Im-
ages are acquired with an isotropic 2.5 × 2.5 × 2.5mm3
resolution, with 58 slices to ensure whole brain coverage.
Visual review is performed for identification of poor
quality images by checking for: (i) full brain coverage;
(ii) inter-acquisition motion (using motion plots over the
acquisition); (iii) sufficient correction of geometric
distortion; and (iv) slice-wise signal dropout (using cor-
relation plots between adjacent slices). Images failing
this quality-control process are removed before running
the diffusion analysis. For each participant, if the
number of acquisitions that have failed is high enough
that it might affect the consistency of the analysis
between subjects, then these data are marked as a ‘failed
acquisition’.
Pre-processing of diffusion-weighted images involves
first correcting for inter-volume motion registration and
eddy currents using FSL’s Eddy tool [96]. This is
followed by correction for EPI susceptibility distortion
using field maps to the structural T1 [97] and phase-
encode direction constrained non -linear registration to
the T1 volume, with modulation based on the
Jacobian determinants. The separate diffusion-
weighted shells (together with their associated b = 0
volumes) are fitted with a diffusion tensor model
using NiftyFit [98]. The NODDI model is then fitted
to the combined shells [93] (see Fig. 5 for an example
of the diffusion-weighted images and corresponding
parameter maps).
3D T2*/SWI
T2*/SWI are iron-sensitive sequences that allow for
detection of cerebral microbleeds, associated with
cerebral small vessel disease or cerebral amyloid angio-
pathy, generally distinguished by their distribution
within the brain parenchyma. Microbleeds are more
common in AD than controls [99], and may independ-
ently impact on cognitive function with potential mecha-
nisms including tissue necrosis in strategic white-matter
tracts [100], or via the initiation of an inflammatory
cascade [100].
A 3D multi-echo gradient echo sequence is ac-
quired to generate T2*-weighted images, T2* maps,
SWI, and quantitative susceptibility maps (qSM). This
sequence can also provide b0 field mapping at higher
resolution than the GRE-based field maps that are
currently often used for processing geometric distor-
tion correction of the DWI and fMRI. The sequence
acquires magnitude and phase images at three echo
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times: TE = 4.92, 9.84, and 19.7 ms (chosen to keep
fat and water signals in phase). Magnitude images
from the longest TE (19.7 ms) provide the T2*-
weighted volume, which are combined with the phase
images from the same echo time to generate SWI
[101]. T2* maps are generated by fitting the three
magnitude images to a monoexponential decay S = S0.ex-
p.(−TE/T2*), and qSM are obtained from the three phase
images using the superfast dipole inversion (SDI) method
[102]. The images are visually checked for coverage, mo-
tion, and artefacts.
Arterial spin labelling (ASL)
ASL is a non-invasive method for determining
regional cerebral blood flow (CBF). In brief, blood
flowing through the neck vessels is labelled via spin
inversion. After a delay period to allow this labelled
blood to perfuse into the brain, images are acquired,
and compared with equivalent images acquired
without prior spin labelling (unlabelled images). The
signal difference between labelled and unlabelled
images is proportional to blood flow, thus enabling
calculation of a quantitative cerebral blood flow map.
ASL data are acquired using a 4-shot segmented 3D
GRASE pCASL sequence [103] (for more details refer
to Table 4). The ASL timing parameters were chosen
based on the recommendations of the recent ISMRM
Perfusion Study Group consensus paper [104]:
labeling duration =1800 ms; post labelling delay
=1800 ms. Ten averages are acquired and saved
separately, in order to allow image realignment prior
to averaging. Background suppression is used to
reduce static tissue signal, and an accompanying set
of three saturation recovery data sets (TR = 1 s, 2 s,
/2/4 s) are acquired using the same 3D GRASE ac-
quisition scheme for estimation of tissue T1 and M0
(total scan time ~ 50s).
During pre-processing, CBF maps are calculated
using the recommended model for ASL images
acquired with a single post-labelling delay [104],
implemented in NiftyFit [98] and assuming blood
T1 at 3 T of 1650 ms and an overall labelling effi-
ciency of 0.833 (blood inversion efficiency of 0.85
and two background suppression pulses with inver-
sion efficiency 0.99 each). The saturation recovery
data are fitted to a monoexponential recovery curve
to estimate the underlying tissue magnetisation
(M0) and receiver coil sensitivity variation, enabling
generation of quantitative CBF maps [98]. Error
maps are also provided to allow inference of how
precisely CBF in different regions has been estimated.
Primary imaging pipelines and analyses
All imaging data, derived results, visual quality
checks, and radiological reads are stored on a custo-
mised web-based server running XNAT 1.6.5
(www.xnat.org). As protected health information
(PHI) is stored in the proprietary listmode format,
but difficult to remove, the decision was made not to
enter any PHI on the scanner console of these parti-
cipants. After data are acquired on the PET/MR
scanner they are transferred to a study-specific
waypoint. This includes both the DICOM-compliant
imaging format used for MRI and PET images that
are reconstructed on the scanner and raw listmode
data that consists of a customised DICOM file which
contains the Interfile header and a corresponding
binary data file generated from the full 60 min of
PET acquisition. Twice daily, all recent data are
securely synchronised between the study-specific
waypoint and the XNAT server, where separate im-
port processes are done for both the DICOM and
listmode data. DICOM data are checked for com-
pleteness before formally importing the data into the
Fig. 5 Representative diffusion images in Insight 46. Examples of diffusion images at the two b values, b = 700 and 2000 s/mm2, with their
corresponding derived MD and FA maps (left) and NODDI metrics (right)
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XNAT database. Once the DICOM data have been
imported, listmode data are then added to the PET-
MR imaging session in the database and automatic
checks are performed to ensure that they contain
the full 60-min acquisition, including some small
amount of time before the tracer was injected. Next,
an in-house workflow management system automat-
ically starts the modality-specific pre-processing
steps mentioned in the previous section. Key derived
images generated during these pre-processing steps
are stored on the XNAT server by attaching them to
the original imaging session. Once pre-processing is
complete, visual review for each modality is per-
formed and a customised modality-specific webform
of the quality checking is stored on the XNAT server.
A consultant neuroradiologist reviews all T1, T2
and FLAIR sequences as outlined in the “Duty of
Care” section by downloading the key imaging data
from the server and completing a customised radio-
logical read web-form within XNAT. Customised
reports are provided to the neuroradiologist which
identify the PET-MR imaging sessions where a read
needs to be completed.
Primary analyses of T1 images include automated
segmentation of whole-brain [105] and hippocampal
regions [106], followed by manual checking and editing,
semi-automated ventricle segmentation, automated total
incracranial volume (TIV) measurement [107] and semi-
automated cortical thickness calculation [108]. Figure 4
provides an example of the GIF segmentation and Fig. 6
shows summary volumetric metrics from the first 100 T1
scans. White-matter burden and micro haemorrhages are
assessed using visual rating scales [109, 110], and
automated quantification [111, 112].
Volume loss between serial scans will be determined
using the robust boundary shift integral (BSI) [113]
following affine registration of repeat and baseline
scans. Regional BSI calculation is performed using a
fully affine whole-brain registration followed by rigid
registration of masked local structures. Tensor-based
morphometry is used as a non-region-based measure
of volume loss.
The amyloid PET images are registered to the T1-scan
and visually rated as positive/negative by experienced
nuclear medicine specialists [114]. Standardised uptake
value ratios (SUVR) are calculated globally and locally
from a T1-parcellation [115]. Regional grey matter
amyloid load is calculated with appropriate partial
volume correction [116].
Blood and urine specimen protocol for clinical samples
and biomarker identification
Blood samples are collected for haemoglobin, platelet
count, urea and creatinine, random glucose, vitamin
B12, and TSH, as potential modulators both of
cognition and progression of Alzheimer’s pathology.
Samples will also be stored for biomarker explor-
ation (both serum and plasma) and genetic analysis.
Blood is collected using a Vacutainer system in a
single venepuncture procedure. Samples are inverted
Fig. 6 Brain volumes derived from first 100 Insight 46 volumetric T1 scans. Violin plots demonstrating total brain and lobar volumes (left) and
regional lobar volumes (right) calculated on the first 100 T1 scans in Insight 46 using the automated segmentation pipeline
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eight times to ensure adequate mixing of blood with
tube additives. All samples are processed within two
hours of collection, as per recent working group
guidelines on biomarker pre-processing [117]. One
4.0 ml EDTA sample is collected for haemoglobin
and platelet count and the remaining sample is
stored at -20 °C prior to genetic extraction. One
2.5 ml SST sample is collected for urea, creatinine,
TSH, vitamin B12 and random glucose. Two 10 ml
EDTA samples and two clotted 8.5 ml SST samples
are spun at 2000 g for 10 min to generate up to
8.0 ml plasma stored as 16 × 0.5 ml aliquots and up
to 7.0 ml serum stored as 14 × 0.5 ml aliquots, all
at -80 °C, for later analysis. Aliqot tubes are made
from polypropylene. Urine is collected in a 100 ml
polypropylene pot and transferred on ice for storage.
A total of 24 ml urine is stored across 5 aliquots at
-80 °C. Planned analyses include measurement of
serum neurofilament light [118], plasma tau [119]
and plasma Aβ40 and Aβ42 [120] using ultrasensi-
tive Single molecule array (Simoa) assays [121].
Genetics
DNA from each participant is extracted from whole
blood using standard methods (phenol-chloroform).
Existing genotyping data are available from the Meta-
bochip [122] and the DrugDev Consortium Array
(Illumina, inc.) and samples are further assayed on
NeuroX2 (Infinium NeuroConsortium Array, Illumina,
inc.) according to the recommended protocol. This
genotyping platform is the second iteration of a
neurological disease-specific array. It covers approxi-
mately 500,000 genetic markers, many of which will
have a role in neurodegenerative disease, and im-
proves on NeuroX which was designed and released
in 2014 [123]. NeuroX2 includes an up-to-date con-
tent, with the latest signals from the most recent
genome-wide association study (GWAS) in neuro-
degenerative diseases, such as PD and AD. As an ex-
ample, all known genome-wide associated and
suggestive loci for AD are present in the array, which
enables the creation and ascertainment of polygenic
risk scores for that disease [15], which can then be
improved by using biomarker and imaging data from
the same participants.
Analysis plan
Overarching themes of the study include better
characterisation of the prevalence and incidence of
cerebral amyloidosis in a British birth cohort; exam-
ining how biological, genetic, psychological and social
factors across life influence cerebrovascular burden,
amyloid burden, and neurodegeneration (as measured
by cortical network breakdown and cerebral atrophy),
and their interplay on cognition; and in doing so es-
tablishing metrics that are sensitive for detecting
early neurodegeneration.
Specific research questions we will address include:
the extent and variability of amyloid deposition and
proportion of this representative cohort who will be
amyloid positive (estimated at 15–25%); the relation-
ships between amyloid load, standard and more ad-
vanced MR metrics and vascular burden; the
influence of childhood cognitive and motor ability,
educational attainment, lifetime mental health, phys-
ical activity, physical function and cerebrovascular risk
profiles and genetic factors on the development of
brain pathology, cognitive health, gait and motor
skills; the cognitive tests – both established and novel
– that are most associated with cross-sectional bio-
markers of brain pathology and have most power to
detect change over time and thus to be outcome
measures for clinical trials; the extent to which gen-
etic risk scores and blood-based biomarkers can de-
tect asymptomatic amyloidosis; and how best to
recruit to presymptomatic AD trials and which im-
aging and other biomarkers will maximise power to
detect treatment effects in the preclinical and very
early stages of cognitive decline.
Discussion
Insight 46 intends to integrate the NSHD data on the
socioeconomic environment and on physical, psycho-
logical and cognitive function from 0 to 69 years,
coupled with data on genetics, structural and molecu-
lar imaging, and intensive cognitive and neurological
phenotyping, to inform what influences the entire
spectrum of changes that occur as the brain ages:
from healthy through to pathological ageing, with a
specific focus on AD. Combining the cohort’s
uniquely rich life course data with the metrics col-
lected in Insight 46, at an age when overt dementia is
rare, provides an unprecedented opportunity to ex-
plore pre-symptomatic neurodegeneration and to
evaluate very subtle cognitive decline. Prospective fol-
low up in the sub-study allows for the consequences
of these changes to be quantified. These analyses,
initially performed in house, with subsequent data
dissemination in line with the MRC Policy on data
sharing, have the potential to provide fundamental
insights into the factors that influence healthy and
pathological brain ageing, provide an evidence base to
inform how best to identify individuals at high risk
for AD and other forms of dementia, and contribute
to practices for monitoring change over time for
clinical trials.
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Abbreviations
3 T: 3 Tesla (magnetic field strength); ACE-III: Addenbrooke’s Cognitive
Examination 3rd revision; AD: Alzheimer’s disease; ASL: arterial spin labelling;
AxD: axial diffusivity; Aβ: beta-amyloid; BRAIN: BRadykinesia Akinesia
INcoordination test; CBF: cerebral blood flow; CDR: Clinical Dementia Rating
scale; DICOM: Digital Imaging and Communications in Medicine, a standard
for handling, storing, printing, and transmitting information in medical
imaging; DVAR: variance of signal change from average signal in fMRI; DW
MRI: diffusion-weighted MRI; EDTA: ethylenediaminetetraacetic acid; EPI: echo
planar imaging; FA: fractional anisotropy; FLAIR: fluid attenuated inversion
recovery MRI; fMRI: functional MRI; FNAME-12A: 12-item Face-Name Associa-
tive Memory Exam; FNAME-16: 16-item Face-Name Associative Memory
Exam; FWHM: full width at half maximum (spatial resolution); GIF: geodesic
information flow, an in-house method of MRI segmentation;
GRAPPA: GeneRalized Autocalibrating Partial Parallel Acquisition, an MRI
multi-coil parallel imaging technique; GRASE: gradient- and spin-echo MRI;
GWAS: genome wide association study; ICA: independent component
analysis; MCI: mild cognitive impairment; MD: mean diffusivity; MMSE:
mini-mental state examination; MPRAGE: magnetisation prepared rapid
gradient echo MRI; MRC: Medical Research Council; MRI: magnetic resonance
imaging; NDI: neurite density index; NODDI: neurite orientation dispersion
and density index; NRES: National Research Ethics Service; NSHD: National
Survey of Health and Development; ODI: orientation dispersion index;
pCASL: pseudo-Continuous Arterial Spin Labelling; PD: Parkinson’s disease;
PEEK: Portable Eye Examination Kit; PET: positron emission tomography;
PHI: protected health information; QC: quality control; RD: radial diffusivity;
REC: research ethics committee; REM: rapid eye movement; SCD-Q: Subjective
Cognitive Decline Questionnaire; SNR: signal-to-noise ratio; SPACE: Sampling
Perfection with Application optimized Contrasts using different flip angle
Evolution MRI; SST: serum-separator tube; SUVR: standardised uptake value ratio;
T1: MRI spin–lattice or longitudinal relaxation time; T2*: MRI measure of loss of
phase coherence among spins oriented at an angle to the static magnetic field
due to a combination of magnetic field inhomogeneities and the spin-spin re-
laxation; T2: MRI spin-spin or transverse relaxation time; TE: MRI echo time;
TR: MRI repetition time; TSH: thyroid-stimulating hormone; UCL: University
College London; UPDRS: Unified Parkinson’s Disease Rating Scale;
UPSIT: University of Pennsylvania Smell Identification Test; UTE: MRI ultrashort
TE; WAIS-R: Wechsler Adult Intelligence Scale-Revised; WASI: Wechsler
Abbreviated Scale of Intelligence; WMS-R: Wechsler Memory Scale-Revised;
XNAT: an open-source imaging informatics software platform
Acknowledgements
We are very grateful to those study members who helped in the design of the
study through focus groups, and to the participants both for their contributions
to Insight 46 and for their commitments to research over the last seven decades.
We are grateful to the radiographers and nuclear medicine physicians (Professor
Ashley Groves, Dr. Jamshed Bomanji, Dr. Irfan Kayani) at the UCL Institute of
Nuclear Medicine, and to the staff at the Leonard Wolfson Experimental
Neurology Centre at UCL. We acknowledge the help of the following
collaborators for their assistance with specific tests included in the protocol,
including Dr. Patrick Esser, Dr. Emily Henderson and Professor Helen Dawes (gait
task); Professor Masud Husain and Dr. Yoni Pertzov (‘What was where?’ visual
short-term memory binding task); Professor Julie Stout (visuomotor integration
task); Professor Nilli Lavie (irrelevant distractor paradigm); Dr. Dorene Rentz, Dr.
Kathryn Papp and Dr. Reisa Sperling (FNAME-12); Dr. Alastair Noyce (BRAIN test);
Dr. Doris Bamiou, Professor Jason Warren, Professor Stuart Rosen and Dr. Tim
Schoof (auditory tasks); Jamie Toombs (wet biomarker preprocessing); Professor
Rebecca Hardy for advice on sample selection and statistical methods; and to
Professor Yoav Ben Shlomo and Professor Aroon Hingorani for advice on gait/
parkinsonism and genetics respectively. We would like to acknowledge Dan
Marcus and Rick Herrick for assistance with XNAT, Dr. Philip Curran for assistance
with data sharing with the MRC Unit for Lifelong Health and Ageing, the DRC
trials team for assistance with imaging QC, and Mark White for his work on data
connectivity. This study is principally funded by grants from Alzheimer’s Research
UK (ARUK-PG2014–1946, ARUK-PG2017–1946), the Medical Research Council
Dementias Platform UK (CSUB19166), and the Wolfson Foundation (PR/ylr/18575).
The genetic analyses are funded by the Brain Research Trust (UCC14191).
Florbetapir amyoid tracer is kindly provided by AVID Radiopharmaceuticals (a
wholly owned subsidiary of Eli Lilly) who had no part in the design of the study:
we are particularly indebted to the support of the late Dr. Chris Clarke of AVID
Radiopharmaceuticals who championed this study from its outset. The NSHD, DK,
MR, NS and AW are funded by the Medical Research Council (MC_UU_12019/1,
MC_UU_12019/3). Some researchers are supported by the NIHR Queen Square
Dementia BRU (JMS, NCF, SMDH), UCL Hospitals Biomedical Research Centre
(JMS,EDV), Leonard Wolfson Experimental Neurology Centre (JMS, NCF, MM,
DT). TP is supported by a Wellcome Trust Clinical Research Fellowship (200109/
Z/15/Z). DMC is supported by an Alzheimer’s Society Project Grant (AS-PG-205).
MM is supported by an Alzheimer’s Society Project Grant (AS-PG-15-025). AM is
supported by an MRC grant (MR/J01107X/1). CS is supported by an MRC
platform grant (EP/M020533/1). SC is supported by an Alzheimer’s Research UK
Senior Research Fellowship (ARUK-SRF2013–8). JH receives grant support from
an Anonymous Foundation. SO receives funding from the EPSRC (EP/H046410/
1, EP/J020990/1, EP/K005278), the MRC (MR/J01107X/1), the EU-FP7 project
VPH-DARE@IT (FP7-ICT-2011-9-601,055), and NIHR BRC UCLH/UCL High Impact
Initiative (BW.mn.BRC10269). NCF is supported by an NIHR Senior Investigator
award, and additional funding from the NIA and EPSRC. JMS acknowledges the
EPSRC (EP/J020990/1) and European Union’s Horizon 2020 research and
innovation programme (Grant 666,992).
Funding
Insight 46 is funded by grants from Alzheimer’s Research UK (ARUK-PG2014–1946,
ARUK-PG2017-1946 PIs Schott, Fox, Richards), the Medical Research Council De-
mentias Platform UK (CSUB19166 PIs Schott, Fox, Richards), the Wolfson Founda-
tion (PR/ylr/18575 PIs Fox, Schott), the Medical Research Council (MC_UU_12019/
1 PI Kuh and MC_UU_12019/3 PI Richards), the Wellcome Trust (Clinical Research
Fellowship 200,109/Z/15/Z Parker) and Brain Research Trust (UCC14191, PI Schott).
AVID Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly) provide the PET
amyloid tracer (Florbetapir) but had no part in the design of the study.
Availability of data and material
Data generated in Insight 46 will be made available one year after each
wave of data collection is completed, allowing sufficient time for quality
control, and confidentiality of imaging data to be assured. Data will be made
available to bona fide researchers through LHA’s standard security processes,
and according to established NSHD data sharing guidelines. Requests for
data will be considered by a data sharing committee on the basis of quality,
scientific priorities and overlapping interests.
Authors’ contributions
CAL, TP, DMC, KM, ED, HM-S wrote parts of the first draft and contributed to the
overall design of the sub-study. AB, DBr, DBe, DMC, NB, MJC, AC, EDV, JD, MH, ME,
JK, IM, PM, AM, MM, CS, DT, HZh, and SO contributed to the design of the im-
aging protocols and analysis pipelines, and critically read the manuscript. ED, KM,
JC, SMDH, SC designed the neuropsychology protocols, and critically read the
manuscript. HM-S, MB, SB, NE, AW contributed to sub-study design, planned the
data management, and critically read the manuscript. JB, AW, JH planned
the genetic analysis plans, and critically read the manuscript. CH, NS and
SS designed the imaging duty of care plan and critically read the manu-
script. NS and AS planned the movement disorders and gait protocols, and critic-
ally read the manuscript. HZe planned the wet biomarker analysis plans, and
critically read the manuscript. DK directs the NSHD, planned the sub-study and
critically revised drafts of this paper. MR and NCF planned the sub-study, obtained
funding, managed the sub-study, and critically revised drafts of this paper. JMS
planned the sub-study, obtained funding, managed the sub-study, drafted aspects of
the paper, and is the guarantor. All authors read and approved the final manuscript.
Competing interests
HZe is a co-founder of Brain Biomarker Solutions, a GU venture-based platform
company at the University of Gothenburg and has served on advisory boards
of Eli Lilly, Roche Diagnostics and Pharmasum Therapeutics. JD is a consultant
for GE Healthcare and Bioclinica. NCF’s research group has received payment
for consultancy or for conducting studies from AVID, Bristol-Myers Squibb, Elan
Pharmaceuticals, Eisai, Lilly Research Laboratories, GE Healthcare, IXICO, Janssen
Alzheimer Immunotherapy, Johnson & Johnson, Janssen-Cilig, Lundbeck,
Neurochem Inc., Pfizer Inc., Sanofi-Aventis and Wyeth Pharmaceuticals. NCF
receives no personal compensation for the activities mentioned above. JS has
received research funding from Avid Radiopharmaceuticals (a wholly owned
subsidiary of Eli Lilly), has consulted for Roche Pharmaceuticals and Eli Lilly, and
serves on a Data Safety Monitoring Committee for Axon Neuroscience SE.
Consent for publication
Not applicable.
Lane et al. BMC Neurology  (2017) 17:75 Page 21 of 25
Ethics approval and consent to participate
Ethical approval for the neuroscience sub-study was granted by the
National Research Ethics Service (NRES) Committee London (REC reference
14/LO/1173, PI Schott). All participants provide written informed consent to
participate and for their data to be stored in accordance with the Data
Protection Act.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Dementia Research Centre, Institute of Neurology, University College
London, London, UK. 2Translational Imaging Group, Centre for Medical Image
Computing, University College London, London, UK. 3Leonard Wolfson
Experimental Neurology Centre, Institute of Neurology, University College
London, London, UK. 4Institute of Nuclear Medicine, University College
London Hospitals, London, UK. 5Department of Molecular Neuroscience,
Institute of Neurology, University College London, London, UK. 6Department
of Medical Sciences and Institute of Biomedicine - iBiMED, University of
Aveiro, Aveiro, Portugal. 7MRC Unit for Lifelong Health and Ageing at UCL,
London, UK. 8Lysholm Department of Neuroradiology, The National Hospital
for Neurology and Neurosurgery, Queen Square, London, UK.
9Neuroradiological Academic Unit, Department of Brain Repair and
Rehabilitation, Institute of Neurology, University College London, London, UK.
10Department of Clinical Neuroscience, Institute of Neurology, University
College London, London, UK. 11National Hospital for Neurology and
Neurosurgery, London, UK. 12Department of Computer Science and Centre
for Medical Image Computing, University College London, London, UK.
13Reta Lila Weston Research Laboratories, Department of Molecular
Neuroscience, Institute of Neurology, University College London, London, UK.
14Department of Psychiatry and Neurochemistry, Institute of Neuroscience
and Physiology, the Sahlgrenska Academy at the University of Gothenburg,
Mölndal, Sweden. 15Clinical Neurochemistry Laboratory, Sahlgrenska
University Hospital, Mölndal, Sweden.
Received: 11 January 2017 Accepted: 21 March 2017
References
1. Office of National Statistics. Deaths Registered in England and Wales;
2016. p. 1–15.
2. Prince M, Albanese E, Guerchet M, Prina M, Richard Pender C, Ferri C, et al.
World Alzheimer. Report 2014 Dementia and Risk Reduction an Analysis of
Protective and Modifiable Factors. 2014.
3. Alzheimer’s Association. Changing the Trajectory of Alzheimer’s Disease: A
National Imperative. Alzheimer’s Assoc. 2010:1–17.
4. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in
different age categories. Neurobiol Aging. 1997;18:351–7.
5. Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, et al.
Clinical and biomarker changes in dominantly inherited Alzheimer’s disease.
N Engl J Med. 2012;367:795–804.
6. Villemagne VL. Burnham S, Bourgeat P, Brown B, Ellis K a, Salvado O,
et al. Amyloid β deposition, neurodegeneration, and cognitive decline in
sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol.
2013;12:357–67.
7. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al.
Toward defining the preclinical stages of Alzheimer’s disease:
recommendations from the National Institute on Aging-Alzheimer’s
association workgroups on diagnostic guidelines for Alzheimer’s disease.
Alzheimers Dement. 2011;7:280–92.
8. Jack CR, Wiste HJ, Weigand SD, Rocca WA, Knopman DS, Mielke MM,
et al. Age-specifi c population frequencies of cerebral β-amyloidosis
and neurodegeneration among people with normal cognitive
function aged 50–89 years: a cross- sectional study. Lancet Neurol
2014;13:997–1005.
9. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al.
Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2
criteria. Lancet Neurol. 2014;13:614–29.
10. Reiman EM, Langbaum JBS, Fleisher AS, Caselli RJ, Chen K, Ayutyanont N,
et al. Alzheimer’s prevention Initiative: a plan to accelerate the evaluation
of presymptomatic treatments. J Alzheimers Dis. 2011;26(Suppl 3):321–9.
11. Mills SM, Mallmann J, Santacruz AM, Fuqua A, Carril M, Aisen PS, et al.
Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU
trial. Rev Neurol. 2013;169:737–43.
12. Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M, Salmon DP, et al.
The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014;6:
228fs13.
13. Mormino EC. The relevance of Beta-Amyloid on markers of Alzheimer’s
disease in clinically normal individuals and factors that influence these
associations. Neuropsychol Rev. 2014:300–12.
14. Brodaty H, Mothakunnel A, de Vel-Palumbo M, Ames D, Ellis KA,
Reppermund S, et al. Influence of population versus convenience
sampling on sample characteristics in studies of cognitive aging.
Ann Epidemiol. 2014;24:63–71.
15. Escott-Price V, Sims R, Bannister C, Harold D, Vronskaya M, Majounie E, et al.
Common polygenic variation enhances risk prediction for Alzheimer’s
disease. Brain. 2015;138:3673–84.
16. Xu W, Tan L, Wang H-F, Jiang T, Tan M-S, Tan L, et al. Meta-analysis of
modifiable risk factors for Alzheimer’s disease. J Neurol Neurosurg
Psychiatry. 2015;86:1299–306.
17. Kuh D, Pierce M, Adams J, Deanfield J, Ekelund U, Friberg P, et al. Cohort
profile: updating the cohort profile for the MRC National Survey of health
and development: a new clinic-based data collection for ageing research.
Int J Epidemiol. 2011;40
18. Wadsworth M, Kuh D, Richards M, Hardy R. Cohort profile: the 1946 National
Birth Cohort (MRC National Survey of health and development). Int J Epidemiol.
2006;35:49–54.
19. Kuh D, Wong A, Shah I, Moore A, Popham M, Curran P, et al. The MRC
National Survey of health and development reaches age 70:
maintaining participation at older ages in a birth cohort study.
Eur J Epidemiol. 2016;31:1135–47.
20. Alzheimer’s Association. Alzheimer’s association report: 2014 Alzheimers
disease facts and figures. Alzheimers Dement. 2014;10:e47–92.
21. Hardy R, Ghosh AK, Deanfield J, Kuh D, Hughes AD. Birthweight, childhood
growth and left ventricular structure at age 60–64 years in a British birth
cohort study. Int J Epidemiol. 2016;45(4):1091–102.
22. Medical Research Council, The Wellcome Trust. Framework on the feedback
of health-related findings in research 2014. Available from: https://www.mrc.
ac.uk/documents/pdf/mrc-wellcome-trust-framework-on-the-feedback-of-
health-related-findings-in-researchpdf/.
23. Harkins K, Sankar P, Sperling R, Grill JD, Green RC, Johnson KA, et al.
Development of a process to disclose amyloid imaging results to cognitively
normal older adult research participants. Alzheimers Res Ther. 2015;7:26.
24. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of
idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases.
J Neurol Neurosurg Psychiatry. 1992;55:181–4.
25. Spielberger. State-Trait Anxiety Inventory: A comprehensive bibliography. 1983.
26. Eke PI, Dye BA, Wei L, Slade GD, Thornton-Evans GO, Beck JD, et al. Self-reported
measures for surveillance of periodontitis. J Dent Res. 2013;92:1041–7.
27. Cerajewska TL, Davies M, West NX. Periodontitis: a potential risk factor for
Alzheimer’s disease. BDJ Nature Publishing Group. 2015;218:29–34.
28. Briggs GG, Nebes RD. Patterns of hand preference in a student population.
Cortex. 1975;11:230–8.
29. Bishop DVM. Cerebral asymmetry and language development: cause,
correlate, or consequence? Sci Eur PMC Funders. 2013;340:1230531.
30. Postuma RB, Arnulf I, Hogl B, Iranzo A, Miyamoto T, Dauvilliers Y, et al.
A single-question screen for rapid eye movement sleep behavior disorder:
a multicenter validation study. Mov Disord. 2012;27:913–6.
31. Rami L. Mollica M a, García-Sanchez C, Saldaña J, Sanchez B, Sala I, et al.
The subjective cognitive decline questionnaire (SCD-Q): a validation study.
J Alzheimers Dis. 2014;41:453–66.
32. Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chételat G,
et al. A conceptual framework for research on subjective cognitive decline
in preclinical Alzheimer’s disease. Alzheimers Dement. 2014;10:844–52.
33. Galvin JE, Roe CM, Powlishta KK, Coats MA, Muich SJ, Grant E, et al.
The AD8: a brief informant interview to detect dementia. Neurology.
2005;65:559–64.
34. Galvin JE, Roe CM, Xiong C, Morris JC. Validity and reliability of the AD8
informant interview in dementia. Neurology. 2006;67:1942–8.
Lane et al. BMC Neurology  (2017) 17:75 Page 22 of 25
35. Verghese J, Robbins M, Holtzer R, Zimmerman M, Wang C, Xue X, et al.
Gait dysfunction in mild cognitive impairment syndromes. J Am Geriatr Soc
Blackwell Publishing Inc. 2008;56:1244–51.
36. Buracchio T, Dodge HH, Howieson D, Wasserman D, Kaye J. The trajectory of
gait speed preceding mild cognitive impairment. Arch Neurol. 2010;67:980–6.
37. Hausdorff JM, Yogev G. Cognitive function may be important for fall injury
prevention trials. J Am Geriatr Soc. 2006;54:865.
38. Rota V, Perucca L, Simone A, Tesio L. Walk ratio (step length/cadence)
as a summary index of neuromotor control of gait: application to multiple
sclerosis. Int J Rehabil Res Int Zeitschrift für Rehabil Rev Int Rech
réadaptation. 2011;34:265–9.
39. Collett J, Esser P, Khalil H, Busse M, Quinn L, DeBono K, et al. Insights into
gait disorders: walking variability using phase plot analysis. Huntington’s
disease Gait Posture. 2014;40:694–700.
40. Wilson RS, Schneider JA, Bienias JL, Evans DA, Bennett DA. Parkinsonianlike
signs and risk of incident Alzheimer disease in older persons. Arch Neurol.
2003;60:539–44.
41. Richards M, Stern Y, Mayeux R. Subtle extrapyramidal signs can predict
the development of dementia in elderly individuals. Neurology.
1993;43:2184–8.
42. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et
al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s
disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing
results. Mov Disord. 2008;23:2129–70.
43. Noyce AJ, Nagy A, Acharya S, Hadavi S, Bestwick JP, Fearnley J, et al.
Bradykinesia-akinesia incoordination test: validating an online keyboard test
of upper limb function. PLoS One. 2014;9
44. Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, et al.
The preclinical Alzheimer cognitive composite: measuring amyloid-related
decline. JAMA Neurol. 2014;71:961–70.
45. Hsieh S, Schubert S, Hoon C, Mioshi E, Hodges JR. Validation of the Addenbrooke’s
Cognitive Examination III in Frontotemporal Dementia and Alzheimer’s Disease.
Dementia and Geriatric Cognitive Disorders. 2013;36(3–4):242–50.
46. Silverwood RJ, Richards M, Pierce M, Hardy R, Sattar N, Ferro C, et al.
Cognitive and kidney function: results from a British birth cohort reaching
retirement age. PLoS One. 2014;9:e86743.
47. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. J Psychiatr Res.
1975;12:189–98.
48. Wechsler D. Wechsler memory scale-revised edition. 1987.
49. Wechsler D. Wechsler Adult Intelligence Scale–Revised. 1981.
50. Wechsler D. The Wechsler abbreviated scale of intelligence. San Antonio:
The Psychological Corporation; 1999.
51. Shallice T, Stuss DT, Picton TW, Alexander MP, Gillingham S. Multiple effects
of prefrontal lesions on task-switching. Front Hum Neurosci. 2007;1:2.
52. Aron AR, Monsell S, Sahakian BJ, Robbins TW. A componential analysis of
task-switching deficits associated with lesions of left and right frontal cortex.
Brain. 2004;127:1561–73.
53. Hedden T, Oh H, Younger AP, Patel TA. Meta-analysis of amyloid-cognition
relations in cognitively normal older adults. Neurology. 2013;80:1341–8.
54. Castel AD, Balota DA, Hutchison KA, Logan JM, Yap MJ. Spatial attention
and response control in healthy younger and older adults and individuals
with Alzheimer’s disease: evidence for disproportionate selection
impairments in the Simon task. Neuropsychology. 2007;21:170–82.
55. Hutchison KA, Balota DA, Duchek JM, Ducheck JM. The utility of Stroop task
switching as a marker for early-stage Alzheimer’s disease. Psychol Aging.
2010;25:545–59.
56. Pertzov Y, Miller TD, Gorgoraptis N, Caine D, Schott JM, Butler C, et al. Binding
deficits in memory following medial temporal lobe damage in patients with
voltage-gated potassium channel complex antibody-associated limbic
encephalitis. Brain. 2013;136:2474–85.
57. Pertzov Y, Dong MY, Peich M-C, Husain M. Forgetting what was where: the
fragility of object-location binding. PLoS One. 2012;7:e48214.
58. Parra MA, Abrahams S, Logie RH, Méndez LG, Lopera F, Della SS. Visual
short-term memory binding deficits in familial Alzheimer’s disease. Brain.
2010;133:2702–13.
59. Liang Y, Pertzov Y, Nicholas JM, Henley SMD, Crutch S, Woodward F, et al.
Visual short-term memory binding deficit in familial Alzheimer’s disease.
Cortex. 2016;78:150–64.
60. Pertzov Y, Heider M, Liang Y, Husain M. Effects of healthy ageing on
precision and binding of object location in visual short term memory.
Psychol Aging American Psychological Association. 2015;30:26–35.
61. Say MJ, Jones R, Scahill RI, Dumas EM, Coleman A, Santos RCD, et al.
Visuomotor integration deficits precede clinical onset in Huntington’s
disease. Neuropsychologia Ltd. 2011;49:264–70.
62. Papp KV, Amariglio RE, Dekhtyar M, Roy K, Wigman S, Bamfo R, et al.
Development of a psychometrically equivalent short form of the face-name
associative memory exam for use along the early Alzheimer’s disease
trajectory. Clin. Neuropsychol. 2014;28:771–85.
63. Rentz DM, Amariglio RE, Becker JA, Frey M, Olson LE, Frishe K, et al. Face-name
associative memory performance is related to amyloid burden in normal
elderly. Neuropsychologia. 2011;49:2776–83.
64. Forster S, Lavie N. Failures to ignore entirely irrelevant distractors: the role of
load. J Exp Psychol Appl American Psychological Association. 2008;14:73–83.
65. Forster S, Lavie N. Attentional capture by entirely irrelevant distractors. Vis
Cogn. 2008;16:200–14.
66. Devanand DP, Lee S, Manly J, Andrews H, Schupf N, Doty RL, et al. Olfactory
deficits predict cognitive decline and Alzheimer dementia in an urban
community. Neurology. 2015:182–9.
67. Gates GA, Anderson ML, McCurry SM, Feeney MP, Larson EB. Central
auditory dysfunction as a harbinger of Alzheimer dementia. Arch
Otolaryngol Head Neck Surg. 2011;137:390–5.
68. Lin FR, Albert M. Hearing loss and dementia – who is listening? Aging
Ment. Health. 2014;18:671–3.
69. Hardy CJD, Marshall CR, Golden HL, Clark CN, Mummery CJ, Griffiths TD, et
al. Hearing and dementia. J Neurol. 2016:1–16.
70. Albers MW, Gilmore GC, Kaye J, Murphy C, Wingfield A, Bennett D a., et al.
At the interface of sensory and motor dysfunctions and Alzheimer’s disease.
Alzheimer’s Dement. 2014; 1–29.
71. Bastawrous A, Rono HK, Livingstone IAT, Weiss HA, Jordan S, Kuper H, et al.
Development and validation of a Smartphone-based visual acuity test (Peek
acuity) for clinical practice and community-based fieldwork. JAMA
Ophthalmol. 2015;133:930–7.
72. Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania
Smell Identification Test: a standardized microencapsulated test of olfactory
function. Physiol Behav. 1984;32:489–502.
73. British Society of Audiology. Recommended Procedure bone-conduction
threshold audiometry with and without masking. 2011
74. Rosen S, Souza P, Ekelund C, Majeed A a. Listening to speech in a background
of other talkers: effects of talker number and noise vocoding. J Acoust Soc Am.
2013;133:2431–43.
75. Clark CM. Schneider J a, Bedell BJ, beach TG, bilker WB, Mintun M a, et al. use
of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305:275–83.
76. Burgos N, Cardoso MJ, Modat M, Punwani S, Atkinson D, Arridge SR, et al. CT
synthesis in the head & amp; neck region for PET/MR attenuation correction:
an iterative multi-atlas approach. EJNMMI Phys. 2015 Dec;2(Suppl 1):A31.
77. Burgos N, Cardoso MJ, Thielemans K, Modat M, Pedemonte S, Dickson J, et
al. Attenuation correction synthesis for hybrid PET-MR scanners: application
to brain studies. IEEE Trans Med Imaging. 2014;33:2332–41.
78. Mugler JP, Brookeman JR. Rapid three-dimensional T1-weighted MR imaging
with the MP-RAGE sequence. J Magn Reson Imaging. 1991 Sep-Oct;1(5):561–7.
79. Mugler JP. Optimized three-dimensional fast-spin-echo MRI. J Magn Reson
Imaging. 2014;39:745–67.
80. Jovicich J, Czanner S, Greve D, Haley E, van der Kouwe A, Gollub R, et al.
Reliability in multi-site structural MRI studies: effects of gradient non-linearity
correction on phantom and human data. NeuroImage. 2006;30:436–43.
81. Tustison NJ, Avants BB, Cook PA, Zheng Y, Egan A, Yushkevich PA, et al.
N4ITK: improved N3 bias correction. IEEE Trans Med Imaging. 2010;29:1310–20.
82. Cardoso MJ, Modat M, Wolz R, Melbourne A, Cash D, Rueckert D, et al.
Geodesic information flows: spatially-variant graphs and their application to
segmentation and fusion. IEEE Trans Med Imaging. 2015;34:1976–88.
83. Beckmann CF, DeLuca M, Devlin JT, Smith SM. Investigations into resting-state
connectivity using independent component analysis. Philos. Trans R Soc Lond
B Biol Sci. 2005;360:1001–13.
84. Mennes M, Jenkinson M, Valabregue R, Buitelaar JK, Beckmann C, Smith S.
Optimizing full-brain coverage in human brain MRI through population
distributions of brain size. NeuroImage. 2014 Sep;98:513–20.
85. Power JD, Barnes KA, Snyder AZ, Schlaggar BL, Petersen SE. Spurious but
systematic correlations in functional connectivity MRI networks arise from
subject motion. NeuroImage. 2012;59:2142–54.
86. Modat M, Ridgway GR, Taylor ZA, Lehmann M, Barnes J, Hawkes DJ, et al.
Fast free-form deformation using graphics processing units. Comput
Methods Prog Biomed. 2010;98:278–84.
Lane et al. BMC Neurology  (2017) 17:75 Page 23 of 25
87. Chen G, Saad ZS, Nath AR, Beauchamp MS, Cox RW. FMRI group
analysis combining effect estimates and their variances. NeuroImage.
2012;60:747–65.
88. Glover GH, Li TQ, Ress D. Image-based method for retrospective
correction of physiological motion effects in fMRI: RETROICOR. Magn
Reson Med. 2000;44:162–7.
89. Lohmann G, Stelzer J, Neumann J, Ay N, Turner R. “more is different” in
functional magnetic resonance imaging: a review of recent data analysis
techniques. Brain Connect. 2013;3:223–39.
90. Hütel M, Melbourne A, Thomas D, Rohrer J and Ourselin S. An
overcomplete and efficient ICA for BOLD-fMRI.ISMRM. 2016.
91. Basser PJ, Mattiello J, LeBihan D. MR diffusion tensor spectroscopy and
imaging. Biophys J. 1994;66:259–67.
92. Weston PSJ, Simpson IJA, Ryan NS, Ourselin S, Fox NC. Diffusion imaging
changes in grey matter in Alzheimer’s disease: a potential marker of early
neurodegeneration. Alzheimers Res Ther. 2015;7:47.
93. Zhang H, Schneider T. Wheeler-Kingshott C a., Alexander DC. NODDI:
practical in vivo neurite orientation dispersion and density imaging of the
human brain. NeuroImage. 2012;61:1000–16.
94. Feinberg DA, Jakab PD. Tissue perfusion in humans studied by Fourier
velocity distribution, line scan, and echo-planar imaging. Magn Reson Med.
1990;16:280–93.
95. Reese TG, Heid O, Weisskoff RM, Wedeen VJ. Reduction of eddy-current-induced
distortion in diffusion MRI using a twice-refocused spin echo. Magn Reson Med.
2003;49:177–82.
96. Andersson JLR, Sotiropoulos SN. An integrated approach to correction for
off-resonance effects and subject movement in diffusion MR imaging.
NeuroImage. 2016;125:1063–78.
97. Daga P, Pendse T, Modat M, White M, Mancini L, Winston GP, et al.
Susceptibility artefact correction using dynamic graph cuts: application
to neurosurgery. Med Image Anal. 2014;18:1132–42.
98. Melbourne A, Toussaint N, Owen D, Simpson I, Anthopoulos T,
De Vita E, et al. NiftyFit: a software package for multi-parametric
model-fitting of 4D magnetic resonance imaging data.
Neuroinformatics. 2016;14:319–37.
99. Cordonnier C, van der Flier WM, Attems J, Bayer A, Bullock R, Jones R, et al.
Brain microbleeds and Alzheimer’s disease: innocent observation or key
player? Brain. 2011;134:335–44.
100. Shoamanesh A, Preis SR, Beiser AS, Vasan RS, Benjamin EJ, Kase CS, et al.
Inflammatory biomarkers, cerebral microbleeds, and small vessel disease:
Framingham heart study. Neurology. 2015;84:825–32.
101. Haacke EM, Mittal S, Wu Z, Neelavalli J, Cheng Y-CN. Susceptibility-weighted
imaging: technical aspects and clinical applications, part 1. AJNR Am J
Neuroradiol. 2009;30:19–30.
102. Schweser F, Deistung A, Sommer K, Reichenbach JR. Toward online
reconstruction of quantitative susceptibility maps: superfast dipole inversion.
Magn Reson Med. 2013;69:1581–93.
103. Vidorreta M, Balteau E, Wang Z, De Vita E, Pastor MA, Thomas DL, et al. Evaluation
of segmented 3D acquisition schemes for whole-brain high-resolution arterial
spin labeling at 3 T. NMR Biomed. 2014;27:1387–96.
104. Alsop DC, Detre JA, Golay X, Günther M, Hendrikse J, Hernandez-Garcia L, et
al. Recommended implementation of arterial spin-labeled perfusion MRI
for clinical applications: a consensus of the ISMRM perfusion study
group and the European consortium for ASL in dementia. Magn Reson
Med. 2015;73:102–16.
105. Leung KK, Barnes J, Modat M, Ridgway GR, Bartlett JW, Fox NC, et al. Brain
MAPS: an automated, accurate and robust brain extraction technique using
a template library. NeuroImage. 2011;55:1091–108.
106. Jorge Cardoso M, Leung K, Modat M, Keihaninejad S, Cash D, Barnes J,
et al. STEPS: similarity and truth estimation for propagated
segmentations and its application to hippocampal segmentation and
brain parcelation. Med Image Anal. 2013;17:671–84.
107. Malone IB, Leung KK, Clegg S, Barnes J, Whitwell JL, Ashburner J, et al.
Accurate automatic estimation of total intracranial volume: a nuisance
variable with less nuisance. NeuroImage. 2015;104:366–72.
108. Clarkson MJ, Cardoso MJ, Ridgway GR, Modat M, Leung KK, Rohrer JD, et al.
A comparison of voxel and surface based cortical thickness estimation
methods. NeuroImage. 2011;57:856–65.
109. Gregoire SM, Chaudhary UJ, Brown MM, Yousry TA, Kallis C, Jäger HR, et al.
The Microbleed anatomical rating scale (MARS): reliability of a tool to map
brain microbleeds. Neurology. 2009;73:1759–66.
110. Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjögren M, et al. A
new rating scale for age-related white matter changes applicable to MRI
and CT. Stroke. 2001;32:1318–22.
111. Prins ND, van Straaten ECW, van Dijk EJ, Simoni M, van Schijndel RA,
Vrooman HA, et al. Measuring progression of cerebral white matter lesions
on MRI: visual rating and volumetrics. Neurology. 2004;62:1533–9.
112. Jain S, Sima DM, Ribbens A, Cambron M, Maertens A, Van Hecke W, et al.
Automatic segmentation and volumetry of multiple sclerosis brain lesions
from MR images. NeuroImage Clin. 2015;8:367–75.
113. Leung KK, Clarkson MJ, Bartlett JW, Clegg S, Jack CR, Weiner MW, et al.
Robust atrophy rate measurement in Alzheimer’s disease using multi-site
serial MRI: tissue-specific intensity normalization and parameter selection.
NeuroImage. 2010;50:516–23.
114. Yang L, Rieves D, Ganley C. Brain Amyloid Imaging — FDA Approval of
Florbetapir F18 Injection. http://dx.doi.org/10.1056/NEJMp1208061.
Massachusetts Medical. Society; 2012;
115. Andrews KA, Modat M, Macdonald KE, Yeatman T, Cardoso MJ, Leung KK, et
al. Atrophy rates in asymptomatic Amyloidosis: implications for Alzheimer
prevention trials. PLoS One. 2013;8
116. Erlandsson K, Buvat I, Pretorius PH, Thomas BA, Hutton BF. A review of
partial volume correction techniques for emission tomography and their
applications in neurology, cardiology and oncology. Phys Med Biol.
2012;57:R119–59.
117. O’Bryant SE, Gupta V, Henriksen K, Edwards M, Jeromin A, Lista S, et al.
Guidelines for the standardization of preanalytic variables for blood-based
biomarker studies in Alzheimer’s disease research. Alzheimers Dement.
2015;11:549–60.
118. Rohrer JD, Woollacott IOC, Dick KM, Brotherhood E, Gordon E, Fellows A, et
al. Serum neurofilament light chain protein is a measure of disease intensity
in frontotemporal dementia. Neurology. 2016 Sep;27:87(13).
119. Mattsson N, Zetterberg H, Janelidze S, Insel PS, Andreasson U, Stomrud E, et
al. Plasma tau in Alzheimer disease. Neurology. 2016;87:1827–35.
120. Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, van Westen D, Jeromin A,
et al. Plasma β-amyloid in Alzheimer’s disease and vascular disease. Sci Rep.
2016;6:26801.
121. Gisslén M, Price RW, Andreasson U, Norgren N, Nilsson S, Hagberg L, et al.
Plasma concentration of the Neurofilament light protein (NFL) is a
biomarker of CNS injury in HIV infection: a cross-sectional study.
EBioMedicine. 2016;3:135–40.
122. Shah T, Engmann J, Dale C, Shah S, White J, Giambartolomei C, et al.
Population genomics of Cardiometabolic traits: Design of the University
College London-London School of Hygiene and Tropical Medicine-
Edinburgh-Bristol (UCLEB) consortium. PLoS One. 2013;8:e71345.
123. Nalls MA, Bras J, Hernandez DG, Keller MF, Majounie E, Renton AE, et al.
NeuroX, a fast and efficient genotyping platform for investigation of
neurodegenerative diseases. Neurobiol Aging. 2015;36:1605.e7–12.
124. Gaysina D, Gardner MP, Richards M, Ben-Shlomo Y. Cortisol and cognitive
function in midlife: the role of childhood cognition and educational
attainment. Psychoneuroendocrinology. 2014;47:189–98.
125. Ross JM, Simpson HR. The National Survey of health and development:
1. Educational Attainment Br J Educ Psychol. 1971;41:49–61.
126. Ross JM, Simpson HR. The National Survey of health and development: 2.
Rate of school progress between 8 and 15 years and between 15 and 18
years. Br J Educ Psychol 1971; 41:125–135.
127. Gale CR, Cooper R, Craig L, Elliott J, Kuh D, Richards M, et al. Cognitive
function in childhood and lifetime cognitive change in relation to
mental wellbeing in four cohorts of older people. PLoS One.
2012;7:e44860.
128. Stewart R, Hardy R, Richards M. Associations between skeletal growth in
childhood and cognitive function in mid-life in a 53-year prospective birth
cohort study. PLoS One. 2015;10:e0124163.
129. Albanese E, Hardy R, Wills A, Kuh D, Guralnik J, Richards M. No association
between gain in body mass index across the life course and midlife
cognitive function and cognitive reserve—the 1946 British birth cohort
study. Alzheimers Dement. 2012;8:470–82.
130. Richards M, Hardy R, Wadsworth M. Alcohol consumption and midlife
cognitive change in the British 1946 birth cohort study. Alcohol Alcohol.
2004;40:112–7.
131. Richards M, Strachan D, Hardy R, Kuh D, Wadsworth M. Lung function and
cognitive ability in a longitudinal birth cohort study. Psychosom Med.
2005;67:602–8.
Lane et al. BMC Neurology  (2017) 17:75 Page 24 of 25
132. Richards M, Barnett JH, Xu MK, Croudace TJ, Gaysina D, Kuh D, et al.
Lifetime affect and midlife cognitive function: prospective birth cohort
study. Br J Psychiatry. 2014;204:194–9.
133. Hurst L, Stafford M, Cooper R, Hardy R, Richards M, Kuh D. Lifetime socioeconomic
inequalities in physical and cognitive aging. Am J Public Health. 2013;
103:1641–8.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Lane et al. BMC Neurology  (2017) 17:75 Page 25 of 25
